The docket at midsummer
The second half of 2026 opens with the plaintiff's bar tracking a familiar set of large dockets, a few fresh nine-figure verdicts, and a mass-tort program that has more allocated money than moving cases. This week's recap looks at where the biggest fights stand, what the recent verdicts signal about jury appetite, and which trials will set value benchmarks before the year is out. As always, the numbers below come from public verdict reporting and court records, so treat them as directional until the post-trial motions resolve.
Uber's assault MDL keeps grinding through bellwethers
The multidistrict litigation over rideshare driver sexual assaults remains the most closely watched consolidated proceeding in the plaintiff world. The second bellwether produced a defense-leaning result. A North Carolina federal jury in April found battery but awarded only $5,000 in emotional-distress damages, a number that tells plaintiffs the liability theory can land while the damages proof still needs work. A third bellwether is queued for the back half of the year. The gap between the liability finding and the damages award is the story practitioners should study, because it previews how ordinary juries weigh institutional-negligence claims against a platform when the direct actor is a contractor. The non-delegable-duty and agency questions that drive these cases continue to ripple into ordinary rideshare crash litigation across the auto bar.
The social-media addiction trial is the products event of the fall
A suit brought by 29 state attorneys general accusing Meta of designing Facebook and Instagram to addict young users is set for trial in the second half of 2026. It sits alongside the sprawling personal-injury MDL raising parallel design-defect theories against social platforms. This is a product case dressed as a consumer-protection case, and the defect framing, that engagement-maximizing design is itself the flaw, is the frontier issue for the products bar. A plaintiff-side verdict would reprice the entire category and pull more firms into intake. The design-versus-warning framing at the center of it echoes the doctrinal questions we cover in our product liability reporting.
Camp Lejeune: the money is there, the machine is not
The Camp Lejeune Justice Act program is the clearest example this cycle of a settlement apparatus outrunning its own claims processing. As of mid-July, roughly 3,756 lawsuits sit in the Eastern District of North Carolina, against an administrative pile of more than 400,000 claims submitted to the Navy. The government has allocated $22 billion to pay claims and has paid north of $421 million through its Elective Option track. Yet only a small fraction of claimants, by the government's own accounting, clear the documentation threshold, and no firm bellwether trial dates are set.
The operational lesson is unglamorous but real. The bottleneck is proof of presence and medical causation, not liability or appropriations. Firms holding Lejeune inventory are learning that the value of a claim is now a function of how complete the file is, not how strong the underlying science is. Expert discovery on the water-contamination and causation phases is largely finished, which means the next move is procedural, and the claimants with clean documentation will be the first to see money.
Premises verdicts keep testing the ceiling
Two recent premises results show juries are still willing to go very high when a defendant's conduct reads as indifference. An Orange County, Florida jury returned a verdict reported at roughly $644.75 million against the owners and operators of a Winter Park bar after a patron fell down a staircase and suffered catastrophic injury. Separately, a Prince George's County, Maryland jury awarded about $71.39 million to a man badly hurt escaping a nighttime apartment fire, with the bulk in future medical care and lost earning capacity. Both are the kind of numbers that anchor future demand letters even after remittitur, and both reinforce that catastrophic future-care models are where the leverage lives. We break down premises proof and damages construction in our slip and fall coverage.
The caution for practitioners is the same as always. Headline verdicts survive post-trial review at a discount, and the reported figure is the start of a negotiation, not the settlement value. But the direction is unmistakable. The ceiling on premises damages keeps rising where the future-care number is well built.
The preemption term still hangs over the products bar
The Supreme Court's decision earlier this year cutting back state-law failure-to-warn claims against Monsanto over Roundup labeling continues to reshape mass-tort strategy on federal preemption grounds. The ruling did not end the litigation, but it narrowed the theories available and sent plaintiff firms back to statutes and jurisdictions where the preemption argument has less purchase. The practical takeaway for anyone carrying pesticide, drug, or device inventory is that the approval pathway and the federal regulatory posture now drive case value as much as the injury does. That same dynamic is playing out in medical-device litigation, where the premarket-approval question can decide whether a case exists at all.
The settlement data tells a quieter story
Behind the headline verdicts, the reported settlement numbers are more restrained. The largest publicly disclosed personal-injury settlement so far in 2026 came in around $52 million, and the top ten reported settlements together totaled roughly $177 million across six states. The spread between the biggest verdicts and the biggest settlements is the usual reminder that defendants pay to avoid a runaway jury, not to match one. For most firms, the practical value of a nine-figure verdict is its gravitational pull on the settlement negotiations that never reach a courtroom, not the odds of hitting that number at trial.
Commercial-vehicle cases continue to anchor the middle of that distribution. Reported results this cycle include a $2.75 million settlement for a driver struck by a semi-truck in Tampa, the kind of workmanlike outcome that never makes a headline but pays the firm's overhead and funds the next catastrophic file. The trucking docket rewards early scene work and preservation of the carrier's electronic records, and the firms that move on those artifacts in the first week are the ones converting liability into leverage before the defense audits its own exposure.
Tort reform keeps moving the goalposts
State-level tort reform remains the quiet variable that reprices cases faster than any single verdict. Damages caps, comparative-fault thresholds, and changes to how future medical expenses are proven have all shifted in multiple jurisdictions over the past year, and each change forces a recalculation of case value at intake. A file that pencils out in one state can be marginal across a border. Firms with multistate inventory are building reform tracking into their case-selection process rather than treating it as a trial-eve surprise. The defense bar reads these statutes the day they pass, and plaintiffs who wait until the pretrial conference to account for a new cap are negotiating from behind.
What to watch into the fall
- The third Uber bellwether, and whether a plaintiff can pair a liability finding with a damages number that justifies the inventory so many firms have built.
- The Meta trial, which will either validate or deflate the addiction-as-defect theory across the social-media docket.
- Camp Lejeune's shift from discovery to trial posture, and whether the Elective Option expands its documentation criteria to move more of the 400,000-claim backlog.
- Continued state-level tort-reform activity, where damages caps and comparative-fault changes keep resetting case value jurisdiction by jurisdiction.
The through-line across all of it is that value is migrating toward documentation and away from theory. The firms winning this year are the ones that treat proof-building as an operational discipline, from mass-tort file completeness to future-care modeling in catastrophic cases. That includes the medical-causation rigor that decides high-severity matters, a subject we cover in our medical malpractice reporting. The money, as Camp Lejeune shows, is often already sitting there. The constraint is getting a clean case in front of the people who write the check.